The statistic depicts the leading merger and acquisition deals in the life sciences industry worldwide in the first half of 2018. In the period examined, Bayer's acquisition of Monsanto was the largest M&A deal, with a value of approximately 63 billion U.S. dollars.
Leading merger and acquisition deals in the life sciences segment worldwide in the first half of 2018, by transaction value (in billion U.S. dollars)
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account.
Starter Account
The ideal entry-level account for individual users
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$69 USD $49 USD / Month *
in the first 12 months
Professional Account
Full access
Business Solutions including all features.
* Prices do not include sales tax.
Other statistics that may interest you
Industry overview
5
- Premium Statistic Pharmaceutical market: worldwide revenue 2001-2022
- Premium Statistic Global biotech drug sales 2012-2022
- Premium Statistic Top 10 biotech and pharmaceutical companies based on market cap 2022
- Premium Statistic Top 50 pharmaceutical companies - Rx sales and R&D spending 2021
- Premium Statistic Top pharmaceutical companies by capex growth in 2021
Number of deals
7
- Premium Statistic Planned and actual healthcare and life sciences activity in 2020, by subsector
- Premium Statistic Global number of life sciences sector deals 2013-2021
- Premium Statistic Number of biopharmaceutical deals worldwide 2016-2020, by type
- Basic Statistic Number of cell and gene therapy deals worldwide 2016-2020, by type
- Premium Statistic Number of biopharma M&A deals worldwide 2010-2019, by companies
- Basic Statistic Number of biopharma M&A deals worldwide 2010-2019, by total transaction value
- Premium Statistic Number of biopharma M&A deals worldwide 2010-2019, by industry
Value of deals
5
- Premium Statistic Largest M&A pharmaceutical deals ever as of 2023
- Premium Statistic Global value of life sciences sector deals 2013-2021
- Basic Statistic Top completed life sciences deals based on value globally 2020
- Premium Statistic Value of biopharma M&A deals worldwide 2010-2019, by industry
- Premium Statistic Average value of biopharma M&A deals worldwide 2010-2019, by industry
Mega-merger: BMS/Celgene
5
- Premium Statistic Bristol-Myers Squibb's revenue 2006-2022
- Basic Statistic Bristol-Myers Squibb revenue by segment 2015-2020
- Basic Statistic Celgene's revenue and net income 2006-2018
- Premium Statistic Revenue of Celgene 2016-2018, by therapeutic area
- Premium Statistic Top pharma companies worldwide 2023, by size of R&D pipeline
2021 outlook
4
- Basic Statistic Expected acquisitions of biopharma companies by type of asset 2021
- Basic Statistic Expected investment in biopharma and diagnostic lab services 2021, by type
- Basic Statistic Expected valuation changes in healthcare and life sciences 2021, by subsector
- Premium Statistic Expected investment changes in biopharma and diagnostic lab services 2021
Further related statistics
18
- Pharma and life sciences executives' workforce strategy priorities U.S. 2020
- Value of M&As in the U.S. healthcare and life sciences sector 2009-2021
- Quarterly M&A in the U.S. in healthcare and life sciences sector 2018-2021
- Chinese outbound deals in healthcare industry 2017-2019, by type
- Revenue value from biotechnology companies in Germany 2008-2021
- Biopharmaceutical revenue - statutory health insurance market Germany 2014
- Trust levels towards pharma industry by country 2021
- Trust levels towards biotech/life sciences by country 2021
- Market and growth of global life sciences by sector 2016
- Projected future investments among life sciences companies 2018
- Top large pharma companies in CEO compensation in 2018
- Opinions on integrating technology into life sciences supply chain management 2018
- Breakdown of biotech and pharma CEO compensation 2018, by component
- Leading M&A announced deals Japan H1 2018
- Drugs developed in biotechnology companies in Germany from 2011 to 2016
- U.S. pharmaceutical industry spending on research and development 1990-2021
- Share who would go to alternative doctors visits in Sweden 2015-2018, by age
- Export value of pharmaceuticals from Germany 2002-2021
Further Content: You might find this interesting as well
Statistics
- Pharma and life sciences executives' workforce strategy priorities U.S. 2020
- Value of M&As in the U.S. healthcare and life sciences sector 2009-2021
- Quarterly M&A in the U.S. in healthcare and life sciences sector 2018-2021
- Chinese outbound deals in healthcare industry 2017-2019, by type
- Revenue value from biotechnology companies in Germany 2008-2021
- Biopharmaceutical revenue - statutory health insurance market Germany 2014
- Trust levels towards pharma industry by country 2021
- Trust levels towards biotech/life sciences by country 2021
- Market and growth of global life sciences by sector 2016
- Projected future investments among life sciences companies 2018
- Top large pharma companies in CEO compensation in 2018
- Opinions on integrating technology into life sciences supply chain management 2018
- Breakdown of biotech and pharma CEO compensation 2018, by component
- Leading M&A announced deals Japan H1 2018
- Drugs developed in biotechnology companies in Germany from 2011 to 2016
- U.S. pharmaceutical industry spending on research and development 1990-2021
- Share who would go to alternative doctors visits in Sweden 2015-2018, by age
- Export value of pharmaceuticals from Germany 2002-2021
Genetic Engineering & Biotechnology News. (July 2, 2018). Leading merger and acquisition deals in the life sciences segment worldwide in the first half of 2018, by transaction value (in billion U.S. dollars) [Graph]. In Statista. Retrieved June 10, 2023, from https://www.statista.com/statistics/916606/global-life-sciences-leading-merger-and-acquisition-deal-value/
Genetic Engineering & Biotechnology News. "Leading merger and acquisition deals in the life sciences segment worldwide in the first half of 2018, by transaction value (in billion U.S. dollars)." Chart. July 2, 2018. Statista. Accessed June 10, 2023. https://www.statista.com/statistics/916606/global-life-sciences-leading-merger-and-acquisition-deal-value/
Genetic Engineering & Biotechnology News. (2018). Leading merger and acquisition deals in the life sciences segment worldwide in the first half of 2018, by transaction value (in billion U.S. dollars). Statista. Statista Inc.. Accessed: June 10, 2023. https://www.statista.com/statistics/916606/global-life-sciences-leading-merger-and-acquisition-deal-value/
Genetic Engineering & Biotechnology News. "Leading Merger and Acquisition Deals in The Life Sciences Segment Worldwide in The First Half of 2018, by Transaction Value (in Billion U.S. Dollars)." Statista, Statista Inc., 2 Jul 2018, https://www.statista.com/statistics/916606/global-life-sciences-leading-merger-and-acquisition-deal-value/
Genetic Engineering & Biotechnology News, Leading merger and acquisition deals in the life sciences segment worldwide in the first half of 2018, by transaction value (in billion U.S. dollars) Statista, https://www.statista.com/statistics/916606/global-life-sciences-leading-merger-and-acquisition-deal-value/ (last visited June 10, 2023)
Leading merger and acquisition deals in the life sciences segment worldwide in the first half of 2018, by transaction value (in billion U.S. dollars) [Graph], Genetic Engineering & Biotechnology News, July 2, 2018. [Online]. Available: https://www.statista.com/statistics/916606/global-life-sciences-leading-merger-and-acquisition-deal-value/